SlideShare a Scribd company logo
1 of 23
Macrophage Activation
Syndrome in SJIA
Alexei Grom, MD
Cincinnati Children’s Hospital Medical Center
Macrophage Activation Syndrome
• Caused by excessive activation and multiplication of
predominately two types of immune cells
• cytotoxic CD8+ T cells and
• macrophages
• Excessive activation of these cell leads to massive
inflammation that might be life-threatening
Normal macrophages
• a type of white blood cells that engulfs and destroys microbes and
other foreign substances in a process called phagocytosis
Macrophages in MAS
• Overly activated
• Start phagocytosing and destroying normal blood cells (such as red
blood cells, neutrophils and platelets)
• Destruction of these blood cells leads to a sudden drop in their
numbers and might be life-threatening
Normal cytotoxic T cells
• A cytotoxic T cell (also known CD8+ T-cell or killer T cell) is a T
lymphocyte (another type of white blood cells) that kills cancer cells,
and cells that are infected (particularly with viruses)
Annual Reviews
MAS is a cytokine storm
MAS is a cytokine storm
• Immune cells communicate with each other by sending various
“chemical signals” called cytokines
• some cytokines cause inflammation
• some cytokines reduce inflammation
• In MAS, there is excessive activation and multiplication of
macrophages and cytotoxic T cells that produce too much cytokines
that cause inflammation
MΦ
Proposed Mechanisms of Macrophage Activation
in Hemophagocytic Syndromes
11
CD8+
IFN-γ
GM-CSF
MΦ
MΦ
MΦ
MΦ
MΦMΦ
MΦ
Mo
TNF-α
IL-6
IL-1
IL-18
M-CSF
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
MΦ
MAS and Hemophagocytic Lymphohistiocytosis
• striking clinical similarities between MAS and
hemophagocytic lymphohistiocytosis
• hemophagocytic lymphohistiocytosis is a genetic disease
in which cytotoxic cells have decreased ability to kill cells
infected with viruses
• Mouy R, et al. J Pediatr 1996;129:750
Annual Reviews
MΦ
Proposed Mechanisms of Macrophage Activation
in Hemophagocytic Syndromes
14
CD8+
IFN-γ
GM-CSF
MΦ
MΦ
MΦ
MΦ
MΦMΦ
MΦ
Mo
TNF-α
IL-6
IL-1
IL-18
M-CSF
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
MΦ
CD8+
CD8+
Cytolytic Defects in FHLH
Cytolytic cells cause destruction of target cells by
delivering granules that contain proteins such as
perforin and granzymes
15
death
Infected Cell
Effector Cell
(NK Cell)
Granzyme B
Fusion
Priming
Munc13-4
Munc18-2
Syntaxin 11
Rab27a
Nucleus
Perforin
Signs and Symptoms Macrophage
Activation Syndrome
Macrophage Activation Syndrome
• Patients look very ill, run high fevers
• Laboratory abnormalities:
• Sudden drop in hemoglobin, platelet and neutrophil counts
• Very high serum ferritin
• Impaired liver function
• Increased liver enzymes (Ast, Alt)
• Decreased ability to make proteins involved in blood coagulation
(such as fibrinogen) leading to bleeding
Silverman ED, et al. J Pediatr 1983;103:872.
Hadchouel M, Prieur AM, and Griscelli C. J Pediatr 1985;106:561.
MAS in Pediatric Rheumatology
• Has been reported in association with almost any rheumatic disease
• By far, most common in systemic JIA
• About 80% of reported cases occurred in association with systemic JIA
• SLE, Kawasaki disease
• Prevalence of “overt MAS” in systemic JIA is ~10%
Sawney, et al. Arch Dis Child 2001;85:4210
• Evidence of subclinical MAS in a subgroup of systemic JIA patients with active systemic
disease (~30%)
Bleesing, et al. Arthritis Rheum 2007;56:965
Behrens, et al. J Rheumatol 2007:34:1133
Laboratory monitoring for signs of MAS
• Cell blood count
• Ferritin
• Liver enzymes
• Fibrinogen
• Soluble IL2Rα
• Soluble CD163
MΦ
MAS mechanisms
21
CD8+
IFN-γ
GM-CSF
MΦ
MΦ
MΦ
MΦ
MΦMΦ
MΦ
Mo
TNF-α
IL-6
IL-1
IL-18
M-CSF
sCD163
sIL-2Rα
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
CD8+
MΦ
CD8+
CD8+
Established Treatments of MAS
• High dose corticosteroids
• Cyclosporine A
• Anakinra in some patients
• Etoposide in most difficult cases
Treatments under investigation
• Biologics neutralizing INF-gamma (anti-IFN γ antibodies)
• Biologics neutralizing IL-18 (recombinant IL18BP)
• Jak-Stat inhibitors

More Related Content

What's hot

Approach to vasculitis
Approach to vasculitisApproach to vasculitis
Approach to vasculitisUsman Shams
 
Hemophagocytic lymphohistiocytosis hlh 2019
Hemophagocytic lymphohistiocytosis hlh 2019Hemophagocytic lymphohistiocytosis hlh 2019
Hemophagocytic lymphohistiocytosis hlh 2019Rania Albar
 
pediatric Systemic lupus erythematosus
pediatric Systemic lupus erythematosuspediatric Systemic lupus erythematosus
pediatric Systemic lupus erythematosusrashree-singh
 
Chronic Liver Disease(pediatrics)
Chronic Liver Disease(pediatrics)Chronic Liver Disease(pediatrics)
Chronic Liver Disease(pediatrics)Manoj Ghoda
 
Approach to a patient with vasculitis
Approach to a patient with vasculitisApproach to a patient with vasculitis
Approach to a patient with vasculitisaminanurnova
 
Hemophagocytic Lymphohistiocytosis.pptx
Hemophagocytic Lymphohistiocytosis.pptxHemophagocytic Lymphohistiocytosis.pptx
Hemophagocytic Lymphohistiocytosis.pptxDr. Renesha Islam
 
Systemic sclerosis..scleroderma
Systemic sclerosis..sclerodermaSystemic sclerosis..scleroderma
Systemic sclerosis..sclerodermaPraveen Nagula
 
Vasculitis syndrome an approach -and-basic principles of treatment
Vasculitis syndrome an approach -and-basic principles of treatmentVasculitis syndrome an approach -and-basic principles of treatment
Vasculitis syndrome an approach -and-basic principles of treatmentSachin Verma
 
Thrombotic Thrombocytopenic Purpura.pptx
Thrombotic Thrombocytopenic Purpura.pptxThrombotic Thrombocytopenic Purpura.pptx
Thrombotic Thrombocytopenic Purpura.pptxMarwa Khalifa
 
Hemolytic anemia in children
Hemolytic anemia in childrenHemolytic anemia in children
Hemolytic anemia in childrenImran Iqbal
 
Dermatomyositis
DermatomyositisDermatomyositis
DermatomyositisHarsh shaH
 

What's hot (20)

Approach to vasculitis
Approach to vasculitisApproach to vasculitis
Approach to vasculitis
 
Hemophagocytic lymphohistiocytosis hlh 2019
Hemophagocytic lymphohistiocytosis hlh 2019Hemophagocytic lymphohistiocytosis hlh 2019
Hemophagocytic lymphohistiocytosis hlh 2019
 
Approach to thrombocytopenia.pptx
Approach to  thrombocytopenia.pptxApproach to  thrombocytopenia.pptx
Approach to thrombocytopenia.pptx
 
pediatric Systemic lupus erythematosus
pediatric Systemic lupus erythematosuspediatric Systemic lupus erythematosus
pediatric Systemic lupus erythematosus
 
Sle
SleSle
Sle
 
seminar on MAS
seminar on MASseminar on MAS
seminar on MAS
 
Vasculitis
VasculitisVasculitis
Vasculitis
 
Juvenile Idiopathic Arthritis
Juvenile Idiopathic ArthritisJuvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
 
Chronic Liver Disease(pediatrics)
Chronic Liver Disease(pediatrics)Chronic Liver Disease(pediatrics)
Chronic Liver Disease(pediatrics)
 
Approach to a patient with vasculitis
Approach to a patient with vasculitisApproach to a patient with vasculitis
Approach to a patient with vasculitis
 
Hemophagocytic Lymphohistiocytosis.pptx
Hemophagocytic Lymphohistiocytosis.pptxHemophagocytic Lymphohistiocytosis.pptx
Hemophagocytic Lymphohistiocytosis.pptx
 
Systemic sclerosis..scleroderma
Systemic sclerosis..sclerodermaSystemic sclerosis..scleroderma
Systemic sclerosis..scleroderma
 
Vasculitis syndrome an approach -and-basic principles of treatment
Vasculitis syndrome an approach -and-basic principles of treatmentVasculitis syndrome an approach -and-basic principles of treatment
Vasculitis syndrome an approach -and-basic principles of treatment
 
Fanconi anemia
Fanconi anemia Fanconi anemia
Fanconi anemia
 
Thrombotic Thrombocytopenic Purpura.pptx
Thrombotic Thrombocytopenic Purpura.pptxThrombotic Thrombocytopenic Purpura.pptx
Thrombotic Thrombocytopenic Purpura.pptx
 
Hemolytic anemia in children
Hemolytic anemia in childrenHemolytic anemia in children
Hemolytic anemia in children
 
Vasculitis
VasculitisVasculitis
Vasculitis
 
Approach to arthritis
Approach to arthritisApproach to arthritis
Approach to arthritis
 
Vasculitis
VasculitisVasculitis
Vasculitis
 
Dermatomyositis
DermatomyositisDermatomyositis
Dermatomyositis
 

Similar to Macrophage Activation Syndrome in SJIA - Alexei Grom

Immunosuppressants.pptx
Immunosuppressants.pptxImmunosuppressants.pptx
Immunosuppressants.pptxKedar Bandekar
 
Pathophysiology of multiple sclerosis
Pathophysiology of multiple sclerosisPathophysiology of multiple sclerosis
Pathophysiology of multiple sclerosisDomina Petric
 
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPYROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPYSIVASWAROOP YARASI
 
Inflammation and Healing.ppt
Inflammation and Healing.pptInflammation and Healing.ppt
Inflammation and Healing.pptAdesh81
 
USMLE Step 1 Immunology review
USMLE Step 1 Immunology reviewUSMLE Step 1 Immunology review
USMLE Step 1 Immunology reviewAbril Santos
 
IMMUNOSUPPRESSANT DRUGS.pptx
IMMUNOSUPPRESSANT DRUGS.pptxIMMUNOSUPPRESSANT DRUGS.pptx
IMMUNOSUPPRESSANT DRUGS.pptxMONIKA325654
 
Cellular immune response
Cellular immune responseCellular immune response
Cellular immune responseVishal Kulkarni
 
Hematological changes in systemic diseases
Hematological changes in systemic diseasesHematological changes in systemic diseases
Hematological changes in systemic diseasesJanani Mathialagan
 
Chronic Myeloid Leukemia
Chronic Myeloid LeukemiaChronic Myeloid Leukemia
Chronic Myeloid Leukemiadocaneesh
 
Chronic Myelogenous Leukemia
Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia
Chronic Myelogenous LeukemiaAneesh Bhandary
 
Leukocyte disorders akk
Leukocyte disorders akkLeukocyte disorders akk
Leukocyte disorders akkAskin Kaplan
 
leukocyte disorders.pptx
leukocyte disorders.pptxleukocyte disorders.pptx
leukocyte disorders.pptxAskin Kaplan
 

Similar to Macrophage Activation Syndrome in SJIA - Alexei Grom (20)

Immunosuppressants.pptx
Immunosuppressants.pptxImmunosuppressants.pptx
Immunosuppressants.pptx
 
Cytokines
CytokinesCytokines
Cytokines
 
Pathophysiology of multiple sclerosis
Pathophysiology of multiple sclerosisPathophysiology of multiple sclerosis
Pathophysiology of multiple sclerosis
 
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPYROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
 
T cell development, maturation, activation and differentiation
T cell development, maturation, activation and differentiationT cell development, maturation, activation and differentiation
T cell development, maturation, activation and differentiation
 
Inflammation and Healing.ppt
Inflammation and Healing.pptInflammation and Healing.ppt
Inflammation and Healing.ppt
 
USMLE Step 1 Immunology review
USMLE Step 1 Immunology reviewUSMLE Step 1 Immunology review
USMLE Step 1 Immunology review
 
Bleeding disorders
Bleeding disordersBleeding disorders
Bleeding disorders
 
IMMUNOSUPPRESSANT DRUGS.pptx
IMMUNOSUPPRESSANT DRUGS.pptxIMMUNOSUPPRESSANT DRUGS.pptx
IMMUNOSUPPRESSANT DRUGS.pptx
 
Haematology Tutorial
Haematology TutorialHaematology Tutorial
Haematology Tutorial
 
Cellular immune response
Cellular immune responseCellular immune response
Cellular immune response
 
IVMS-Gen Path-Inflammation
IVMS-Gen Path-InflammationIVMS-Gen Path-Inflammation
IVMS-Gen Path-Inflammation
 
Plt disorders 2015
Plt disorders 2015Plt disorders 2015
Plt disorders 2015
 
Hematopoisis
HematopoisisHematopoisis
Hematopoisis
 
Hematological changes in systemic diseases
Hematological changes in systemic diseasesHematological changes in systemic diseases
Hematological changes in systemic diseases
 
adaptive immunity
adaptive immunityadaptive immunity
adaptive immunity
 
Chronic Myeloid Leukemia
Chronic Myeloid LeukemiaChronic Myeloid Leukemia
Chronic Myeloid Leukemia
 
Chronic Myelogenous Leukemia
Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia
Chronic Myelogenous Leukemia
 
Leukocyte disorders akk
Leukocyte disorders akkLeukocyte disorders akk
Leukocyte disorders akk
 
leukocyte disorders.pptx
leukocyte disorders.pptxleukocyte disorders.pptx
leukocyte disorders.pptx
 

More from Systemic JIA Foundation

Leading Quality Improvements in Pediatric Rheumatology Care - Dr. Esi Morgan
Leading Quality Improvements in Pediatric Rheumatology Care - Dr. Esi MorganLeading Quality Improvements in Pediatric Rheumatology Care - Dr. Esi Morgan
Leading Quality Improvements in Pediatric Rheumatology Care - Dr. Esi MorganSystemic JIA Foundation
 
What is SJIA - How is it different than other diseases - Dr. Hermine Brunner
What is SJIA - How is it different than other diseases - Dr. Hermine BrunnerWhat is SJIA - How is it different than other diseases - Dr. Hermine Brunner
What is SJIA - How is it different than other diseases - Dr. Hermine BrunnerSystemic JIA Foundation
 
Current Clinical Trials in SJIA & MAS - Dr. Daniel Lovell
Current Clinical Trials in SJIA & MAS - Dr. Daniel LovellCurrent Clinical Trials in SJIA & MAS - Dr. Daniel Lovell
Current Clinical Trials in SJIA & MAS - Dr. Daniel LovellSystemic JIA Foundation
 
Research Updates in SJIA & MAS - Grant Schulert
Research Updates in SJIA & MAS - Grant SchulertResearch Updates in SJIA & MAS - Grant Schulert
Research Updates in SJIA & MAS - Grant SchulertSystemic JIA Foundation
 
Treating new and refractory SJIA patients - Jennifer Huggins
Treating new and refractory SJIA patients - Jennifer HugginsTreating new and refractory SJIA patients - Jennifer Huggins
Treating new and refractory SJIA patients - Jennifer HugginsSystemic JIA Foundation
 
COPA mutations impair Golgi-ER transport causing hereditary autoimmune-mediat...
COPA mutations impair Golgi-ER transport causing hereditary autoimmune-mediat...COPA mutations impair Golgi-ER transport causing hereditary autoimmune-mediat...
COPA mutations impair Golgi-ER transport causing hereditary autoimmune-mediat...Systemic JIA Foundation
 
Childrens Interstitial Lung Disease Clinical Overview
Childrens Interstitial Lung Disease Clinical OverviewChildrens Interstitial Lung Disease Clinical Overview
Childrens Interstitial Lung Disease Clinical OverviewSystemic JIA Foundation
 
Molecular Mechanisms in ILD in Adult Connective Tissue Disease
Molecular Mechanisms in ILD in Adult Connective Tissue DiseaseMolecular Mechanisms in ILD in Adult Connective Tissue Disease
Molecular Mechanisms in ILD in Adult Connective Tissue DiseaseSystemic JIA Foundation
 
Epigenetics and cell fate in JIA and pulmonary fibrosis by Jim Hagood
Epigenetics and cell fate in JIA and pulmonary fibrosis by Jim HagoodEpigenetics and cell fate in JIA and pulmonary fibrosis by Jim Hagood
Epigenetics and cell fate in JIA and pulmonary fibrosis by Jim HagoodSystemic JIA Foundation
 
Immune Mechanisms of Inflamation in SJIA
Immune Mechanisms of Inflamation in SJIAImmune Mechanisms of Inflamation in SJIA
Immune Mechanisms of Inflamation in SJIASystemic JIA Foundation
 

More from Systemic JIA Foundation (14)

Social hour - Rare Disease Day 2023
Social hour - Rare Disease Day 2023 Social hour - Rare Disease Day 2023
Social hour - Rare Disease Day 2023
 
Adult-Onset Still's Disease
Adult-Onset Still's DiseaseAdult-Onset Still's Disease
Adult-Onset Still's Disease
 
New Treatments for SJIA
New Treatments for SJIANew Treatments for SJIA
New Treatments for SJIA
 
Leading Quality Improvements in Pediatric Rheumatology Care - Dr. Esi Morgan
Leading Quality Improvements in Pediatric Rheumatology Care - Dr. Esi MorganLeading Quality Improvements in Pediatric Rheumatology Care - Dr. Esi Morgan
Leading Quality Improvements in Pediatric Rheumatology Care - Dr. Esi Morgan
 
What is SJIA - How is it different than other diseases - Dr. Hermine Brunner
What is SJIA - How is it different than other diseases - Dr. Hermine BrunnerWhat is SJIA - How is it different than other diseases - Dr. Hermine Brunner
What is SJIA - How is it different than other diseases - Dr. Hermine Brunner
 
Current Clinical Trials in SJIA & MAS - Dr. Daniel Lovell
Current Clinical Trials in SJIA & MAS - Dr. Daniel LovellCurrent Clinical Trials in SJIA & MAS - Dr. Daniel Lovell
Current Clinical Trials in SJIA & MAS - Dr. Daniel Lovell
 
Research Updates in SJIA & MAS - Grant Schulert
Research Updates in SJIA & MAS - Grant SchulertResearch Updates in SJIA & MAS - Grant Schulert
Research Updates in SJIA & MAS - Grant Schulert
 
Treating new and refractory SJIA patients - Jennifer Huggins
Treating new and refractory SJIA patients - Jennifer HugginsTreating new and refractory SJIA patients - Jennifer Huggins
Treating new and refractory SJIA patients - Jennifer Huggins
 
COPA mutations impair Golgi-ER transport causing hereditary autoimmune-mediat...
COPA mutations impair Golgi-ER transport causing hereditary autoimmune-mediat...COPA mutations impair Golgi-ER transport causing hereditary autoimmune-mediat...
COPA mutations impair Golgi-ER transport causing hereditary autoimmune-mediat...
 
Childrens Interstitial Lung Disease Clinical Overview
Childrens Interstitial Lung Disease Clinical OverviewChildrens Interstitial Lung Disease Clinical Overview
Childrens Interstitial Lung Disease Clinical Overview
 
Molecular Mechanisms in ILD in Adult Connective Tissue Disease
Molecular Mechanisms in ILD in Adult Connective Tissue DiseaseMolecular Mechanisms in ILD in Adult Connective Tissue Disease
Molecular Mechanisms in ILD in Adult Connective Tissue Disease
 
Epigenetics and cell fate in JIA and pulmonary fibrosis by Jim Hagood
Epigenetics and cell fate in JIA and pulmonary fibrosis by Jim HagoodEpigenetics and cell fate in JIA and pulmonary fibrosis by Jim Hagood
Epigenetics and cell fate in JIA and pulmonary fibrosis by Jim Hagood
 
Rare Pulmonary Diseases in Systemic JIA
Rare Pulmonary Diseases in Systemic JIARare Pulmonary Diseases in Systemic JIA
Rare Pulmonary Diseases in Systemic JIA
 
Immune Mechanisms of Inflamation in SJIA
Immune Mechanisms of Inflamation in SJIAImmune Mechanisms of Inflamation in SJIA
Immune Mechanisms of Inflamation in SJIA
 

Recently uploaded

POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.Silpa
 
Dr. E. Muralinath_ Blood indices_clinical aspects
Dr. E. Muralinath_ Blood indices_clinical  aspectsDr. E. Muralinath_ Blood indices_clinical  aspects
Dr. E. Muralinath_ Blood indices_clinical aspectsmuralinath2
 
TransientOffsetin14CAftertheCarringtonEventRecordedbyPolarTreeRings
TransientOffsetin14CAftertheCarringtonEventRecordedbyPolarTreeRingsTransientOffsetin14CAftertheCarringtonEventRecordedbyPolarTreeRings
TransientOffsetin14CAftertheCarringtonEventRecordedbyPolarTreeRingsSérgio Sacani
 
Use of mutants in understanding seedling development.pptx
Use of mutants in understanding seedling development.pptxUse of mutants in understanding seedling development.pptx
Use of mutants in understanding seedling development.pptxRenuJangid3
 
Factory Acceptance Test( FAT).pptx .
Factory Acceptance Test( FAT).pptx       .Factory Acceptance Test( FAT).pptx       .
Factory Acceptance Test( FAT).pptx .Poonam Aher Patil
 
Chemistry 5th semester paper 1st Notes.pdf
Chemistry 5th semester paper 1st Notes.pdfChemistry 5th semester paper 1st Notes.pdf
Chemistry 5th semester paper 1st Notes.pdfSumit Kumar yadav
 
300003-World Science Day For Peace And Development.pptx
300003-World Science Day For Peace And Development.pptx300003-World Science Day For Peace And Development.pptx
300003-World Science Day For Peace And Development.pptxryanrooker
 
Genetics and epigenetics of ADHD and comorbid conditions
Genetics and epigenetics of ADHD and comorbid conditionsGenetics and epigenetics of ADHD and comorbid conditions
Genetics and epigenetics of ADHD and comorbid conditionsbassianu17
 
FAIRSpectra - Enabling the FAIRification of Analytical Science
FAIRSpectra - Enabling the FAIRification of Analytical ScienceFAIRSpectra - Enabling the FAIRification of Analytical Science
FAIRSpectra - Enabling the FAIRification of Analytical ScienceAlex Henderson
 
Cyanide resistant respiration pathway.pptx
Cyanide resistant respiration pathway.pptxCyanide resistant respiration pathway.pptx
Cyanide resistant respiration pathway.pptxSilpa
 
Genome sequencing,shotgun sequencing.pptx
Genome sequencing,shotgun sequencing.pptxGenome sequencing,shotgun sequencing.pptx
Genome sequencing,shotgun sequencing.pptxSilpa
 
Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....
Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....
Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....muralinath2
 
LUNULARIA -features, morphology, anatomy ,reproduction etc.
LUNULARIA -features, morphology, anatomy ,reproduction etc.LUNULARIA -features, morphology, anatomy ,reproduction etc.
LUNULARIA -features, morphology, anatomy ,reproduction etc.Silpa
 
Module for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learningModule for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learninglevieagacer
 
GBSN - Biochemistry (Unit 2) Basic concept of organic chemistry
GBSN - Biochemistry (Unit 2) Basic concept of organic chemistry GBSN - Biochemistry (Unit 2) Basic concept of organic chemistry
GBSN - Biochemistry (Unit 2) Basic concept of organic chemistry Areesha Ahmad
 
Call Girls Ahmedabad +917728919243 call me Independent Escort Service
Call Girls Ahmedabad +917728919243 call me Independent Escort ServiceCall Girls Ahmedabad +917728919243 call me Independent Escort Service
Call Girls Ahmedabad +917728919243 call me Independent Escort Serviceshivanisharma5244
 
Molecular markers- RFLP, RAPD, AFLP, SNP etc.
Molecular markers- RFLP, RAPD, AFLP, SNP etc.Molecular markers- RFLP, RAPD, AFLP, SNP etc.
Molecular markers- RFLP, RAPD, AFLP, SNP etc.Silpa
 
Proteomics: types, protein profiling steps etc.
Proteomics: types, protein profiling steps etc.Proteomics: types, protein profiling steps etc.
Proteomics: types, protein profiling steps etc.Silpa
 

Recently uploaded (20)

POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.POGONATUM : morphology, anatomy, reproduction etc.
POGONATUM : morphology, anatomy, reproduction etc.
 
Dr. E. Muralinath_ Blood indices_clinical aspects
Dr. E. Muralinath_ Blood indices_clinical  aspectsDr. E. Muralinath_ Blood indices_clinical  aspects
Dr. E. Muralinath_ Blood indices_clinical aspects
 
Clean In Place(CIP).pptx .
Clean In Place(CIP).pptx                 .Clean In Place(CIP).pptx                 .
Clean In Place(CIP).pptx .
 
TransientOffsetin14CAftertheCarringtonEventRecordedbyPolarTreeRings
TransientOffsetin14CAftertheCarringtonEventRecordedbyPolarTreeRingsTransientOffsetin14CAftertheCarringtonEventRecordedbyPolarTreeRings
TransientOffsetin14CAftertheCarringtonEventRecordedbyPolarTreeRings
 
Use of mutants in understanding seedling development.pptx
Use of mutants in understanding seedling development.pptxUse of mutants in understanding seedling development.pptx
Use of mutants in understanding seedling development.pptx
 
Factory Acceptance Test( FAT).pptx .
Factory Acceptance Test( FAT).pptx       .Factory Acceptance Test( FAT).pptx       .
Factory Acceptance Test( FAT).pptx .
 
Chemistry 5th semester paper 1st Notes.pdf
Chemistry 5th semester paper 1st Notes.pdfChemistry 5th semester paper 1st Notes.pdf
Chemistry 5th semester paper 1st Notes.pdf
 
300003-World Science Day For Peace And Development.pptx
300003-World Science Day For Peace And Development.pptx300003-World Science Day For Peace And Development.pptx
300003-World Science Day For Peace And Development.pptx
 
Genetics and epigenetics of ADHD and comorbid conditions
Genetics and epigenetics of ADHD and comorbid conditionsGenetics and epigenetics of ADHD and comorbid conditions
Genetics and epigenetics of ADHD and comorbid conditions
 
FAIRSpectra - Enabling the FAIRification of Analytical Science
FAIRSpectra - Enabling the FAIRification of Analytical ScienceFAIRSpectra - Enabling the FAIRification of Analytical Science
FAIRSpectra - Enabling the FAIRification of Analytical Science
 
Cyanide resistant respiration pathway.pptx
Cyanide resistant respiration pathway.pptxCyanide resistant respiration pathway.pptx
Cyanide resistant respiration pathway.pptx
 
Genome sequencing,shotgun sequencing.pptx
Genome sequencing,shotgun sequencing.pptxGenome sequencing,shotgun sequencing.pptx
Genome sequencing,shotgun sequencing.pptx
 
Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....
Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....
Human & Veterinary Respiratory Physilogy_DR.E.Muralinath_Associate Professor....
 
LUNULARIA -features, morphology, anatomy ,reproduction etc.
LUNULARIA -features, morphology, anatomy ,reproduction etc.LUNULARIA -features, morphology, anatomy ,reproduction etc.
LUNULARIA -features, morphology, anatomy ,reproduction etc.
 
Module for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learningModule for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learning
 
GBSN - Biochemistry (Unit 2) Basic concept of organic chemistry
GBSN - Biochemistry (Unit 2) Basic concept of organic chemistry GBSN - Biochemistry (Unit 2) Basic concept of organic chemistry
GBSN - Biochemistry (Unit 2) Basic concept of organic chemistry
 
Call Girls Ahmedabad +917728919243 call me Independent Escort Service
Call Girls Ahmedabad +917728919243 call me Independent Escort ServiceCall Girls Ahmedabad +917728919243 call me Independent Escort Service
Call Girls Ahmedabad +917728919243 call me Independent Escort Service
 
PATNA CALL GIRLS 8617370543 LOW PRICE ESCORT SERVICE
PATNA CALL GIRLS 8617370543 LOW PRICE ESCORT SERVICEPATNA CALL GIRLS 8617370543 LOW PRICE ESCORT SERVICE
PATNA CALL GIRLS 8617370543 LOW PRICE ESCORT SERVICE
 
Molecular markers- RFLP, RAPD, AFLP, SNP etc.
Molecular markers- RFLP, RAPD, AFLP, SNP etc.Molecular markers- RFLP, RAPD, AFLP, SNP etc.
Molecular markers- RFLP, RAPD, AFLP, SNP etc.
 
Proteomics: types, protein profiling steps etc.
Proteomics: types, protein profiling steps etc.Proteomics: types, protein profiling steps etc.
Proteomics: types, protein profiling steps etc.
 

Macrophage Activation Syndrome in SJIA - Alexei Grom

  • 1. Macrophage Activation Syndrome in SJIA Alexei Grom, MD Cincinnati Children’s Hospital Medical Center
  • 2. Macrophage Activation Syndrome • Caused by excessive activation and multiplication of predominately two types of immune cells • cytotoxic CD8+ T cells and • macrophages • Excessive activation of these cell leads to massive inflammation that might be life-threatening
  • 3. Normal macrophages • a type of white blood cells that engulfs and destroys microbes and other foreign substances in a process called phagocytosis
  • 4.
  • 5. Macrophages in MAS • Overly activated • Start phagocytosing and destroying normal blood cells (such as red blood cells, neutrophils and platelets) • Destruction of these blood cells leads to a sudden drop in their numbers and might be life-threatening
  • 6.
  • 7. Normal cytotoxic T cells • A cytotoxic T cell (also known CD8+ T-cell or killer T cell) is a T lymphocyte (another type of white blood cells) that kills cancer cells, and cells that are infected (particularly with viruses)
  • 9. MAS is a cytokine storm
  • 10. MAS is a cytokine storm • Immune cells communicate with each other by sending various “chemical signals” called cytokines • some cytokines cause inflammation • some cytokines reduce inflammation • In MAS, there is excessive activation and multiplication of macrophages and cytotoxic T cells that produce too much cytokines that cause inflammation
  • 11. MΦ Proposed Mechanisms of Macrophage Activation in Hemophagocytic Syndromes 11 CD8+ IFN-γ GM-CSF MΦ MΦ MΦ MΦ MΦMΦ MΦ Mo TNF-α IL-6 IL-1 IL-18 M-CSF CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ MΦ
  • 12. MAS and Hemophagocytic Lymphohistiocytosis • striking clinical similarities between MAS and hemophagocytic lymphohistiocytosis • hemophagocytic lymphohistiocytosis is a genetic disease in which cytotoxic cells have decreased ability to kill cells infected with viruses • Mouy R, et al. J Pediatr 1996;129:750
  • 14. MΦ Proposed Mechanisms of Macrophage Activation in Hemophagocytic Syndromes 14 CD8+ IFN-γ GM-CSF MΦ MΦ MΦ MΦ MΦMΦ MΦ Mo TNF-α IL-6 IL-1 IL-18 M-CSF CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ MΦ CD8+ CD8+
  • 15. Cytolytic Defects in FHLH Cytolytic cells cause destruction of target cells by delivering granules that contain proteins such as perforin and granzymes 15 death Infected Cell Effector Cell (NK Cell) Granzyme B Fusion Priming Munc13-4 Munc18-2 Syntaxin 11 Rab27a Nucleus Perforin
  • 16. Signs and Symptoms Macrophage Activation Syndrome
  • 17. Macrophage Activation Syndrome • Patients look very ill, run high fevers • Laboratory abnormalities: • Sudden drop in hemoglobin, platelet and neutrophil counts • Very high serum ferritin • Impaired liver function • Increased liver enzymes (Ast, Alt) • Decreased ability to make proteins involved in blood coagulation (such as fibrinogen) leading to bleeding Silverman ED, et al. J Pediatr 1983;103:872. Hadchouel M, Prieur AM, and Griscelli C. J Pediatr 1985;106:561.
  • 18.
  • 19. MAS in Pediatric Rheumatology • Has been reported in association with almost any rheumatic disease • By far, most common in systemic JIA • About 80% of reported cases occurred in association with systemic JIA • SLE, Kawasaki disease • Prevalence of “overt MAS” in systemic JIA is ~10% Sawney, et al. Arch Dis Child 2001;85:4210 • Evidence of subclinical MAS in a subgroup of systemic JIA patients with active systemic disease (~30%) Bleesing, et al. Arthritis Rheum 2007;56:965 Behrens, et al. J Rheumatol 2007:34:1133
  • 20. Laboratory monitoring for signs of MAS • Cell blood count • Ferritin • Liver enzymes • Fibrinogen • Soluble IL2Rα • Soluble CD163
  • 22. Established Treatments of MAS • High dose corticosteroids • Cyclosporine A • Anakinra in some patients • Etoposide in most difficult cases
  • 23. Treatments under investigation • Biologics neutralizing INF-gamma (anti-IFN γ antibodies) • Biologics neutralizing IL-18 (recombinant IL18BP) • Jak-Stat inhibitors

Editor's Notes

  1. Hemophagocytic syndromes are characterized by an uncontrolled expansion of activated CD8 cells that secrete proinflammatory cytokines such as interferon gamma and granulocyte-macrophage colony-stimulating factor. These cytokines cause monocytes to differentiate into macrophages, which then release proinflammatory cytokines, thus causing an exaggerated, cyclical cascade. Persistent activation of macrophages leads to massive increase in proinflammatory cytokines. The mechanism leading to expansion of activated macrophages is not clear. One possible hypothesis for uncontrolled expansion of T cells is a defect in cytolytic function. Reference: Grom AA. Macrophage activation syndrome. In: Cassidy JT, Laxer RM, Petty RE, Lindsley CB, eds. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia, PA: Saunders Elsevier; 2011:674-681.
  2. Hemophagocytic syndromes are characterized by an uncontrolled expansion of activated CD8 cells that secrete proinflammatory cytokines such as interferon gamma and granulocyte-macrophage colony-stimulating factor. These cytokines cause monocytes to differentiate into macrophages, which then release proinflammatory cytokines, thus causing an exaggerated, cyclical cascade. Persistent activation of macrophages leads to massive increase in proinflammatory cytokines. The mechanism leading to expansion of activated macrophages is not clear. One possible hypothesis for uncontrolled expansion of T cells is a defect in cytolytic function. Reference: Grom AA. Macrophage activation syndrome. In: Cassidy JT, Laxer RM, Petty RE, Lindsley CB, eds. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia, PA: Saunders Elsevier; 2011:674-681.
  3. This figure denotes the cytolytic pathway and potential mutations that may be involved. The activity of cytolytic cells is mediated by release of cytotoxic granules that contain proteins such as perforin and granzymes.1 On recognition of the target cells, the cytolytic cells reorganize the cytoskeleton and the microtubule (MT)-organizing center moves toward the site of contact between the cytolytic cell and the target cell, which is called the “immunologic synapse.”2 Cytolytic granules move along the MTs and degranulate at the point of contact.1,2 Perforin is a key cytolytic protein that acts by inserting itself in the membrane of the target cell and delivers content of granules to the target cell.1 References: Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289-298. Filipovich AH. Hemophagocytic lymphohistiocytosis and other hemophagocytic disorders. Immunol Allergy Clin North Am. 2008;28(2):293-313.
  4. Hemophagocytic syndromes are characterized by an uncontrolled expansion of activated CD8 cells that secrete proinflammatory cytokines such as interferon gamma and granulocyte-macrophage colony-stimulating factor. These cytokines cause monocytes to differentiate into macrophages, which then release proinflammatory cytokines, thus causing an exaggerated, cyclical cascade. Persistent activation of macrophages leads to massive increase in proinflammatory cytokines. The mechanism leading to expansion of activated macrophages is not clear. One possible hypothesis for uncontrolled expansion of T cells is a defect in cytolytic function. Reference: Grom AA. Macrophage activation syndrome. In: Cassidy JT, Laxer RM, Petty RE, Lindsley CB, eds. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia, PA: Saunders Elsevier; 2011:674-681.